AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · IEX Real-Time Price · USD
2.470
+0.090 (3.78%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Company Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.

It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease.

The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.
AN2 Therapeutics logo
Country United States
Founded 2017
IPO Date Mar 25, 2022
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Eric E. Easom

Contact Details

Address:
1800 El Camino Real, Suite D
Menlo Park, California 94027
United States
Phone (650) 331-9090
Website an2therapeutics.com

Stock Details

Ticker Symbol ANTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001880438
CUSIP Number 037326105
ISIN Number US0373261058
Employer ID 82-0606654
SIC Code 2834

Key Executives

Name Position
Joseph S. Zakrzewski Co-founder and Chairman of the Board
Eric E. Easom Co-founder, Chief Executive Officer, President and Director
Joshua Eizen J.D. Chief Legal Officer and Secretary
Dr. Paul Eckburg M.D. Chief Medical Officer
Dr. George Harrison Talbot FACP, M.D. Co-Founder and Senior Clinical Advisor
Dr. Michael R. K. Alley Ph.D. Co-Founder and Head of Biology
Lucy O. Day CPA Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Sanjay Chanda Ph.D. Chief Development Officer
Kevin Krause B.S., M.B.A. Chief Strategy Officer
Jennifer Huber Senior Vice President of Regulatory Affairs and Quality

Latest SEC Filings

Date Type Title
Apr 10, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Apr 5, 2024 PRE 14A Other preliminary proxy statements
Mar 29, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 29, 2024 10-K Annual Report
Mar 28, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals